THE FIRST 10 MINUTES IN NOVEL DRUG DEVELOPMENT ARE CRUCIAL
Tissue is the Issue
We are a biotech company focused on precision oncology. We have created special procedures to collect tissue samples, in particular to keep cold ischemia times to under 10 minutes. This ensures specimens have a very high sample integrity and preserves the expression of therapeutic targets otherwise lost.
Our method results in substantial benefits for the understanding of tumor biology, the discovery of novel targets and the development of precision cancer therapeutics.
Thank you for visiting us at ASCO 2024.
As always, ASCO has been a blur of fascinating people, countless exciting conversations and an inspiring exchange overall.
Surely, we couldn’t meet all interested parties in person or discuss all topics in depth.
Revisit our highlight topics below and get in touch with us if you want to dive deeper.
Download our poster to explore the details
Identification of a patient tissue-based phosphorylation site as a biomarker for epidermal growth factor receptor (EGFR) activity in non-small cell lung cancer
Our Novel Target ID Process –
Your Gateway to Innovative Drug Development
We create screening-ready novel target packages and partner with the pharmaceutical industry to develop precision cancer therapeutics.
Looking for a development partnership or more information about our novel target pipeline?
The Indivumed Omics Hub –
Your Clinical Portal for Oncology Research
Access curated multi-omics data derived from your patients. The Indivumed Omics Hub is available to members of our Clinical Network.
Interested in the Indivumed Global Clinical Network or a collaborative partnership?
MISSED US AT
THE CONFERENCE?
Our video summary has you covered. Visit our main website to get a complete picture of Indivumed Therapeutics. Check out our videos, latest news, our publications, or get in touch with our team.